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Activation of RAS signalling induced by K-ras/BRAF mutations is a hallmark of colorectal tumours. In addition, Ras association domain
families 1 and 2 (RASSF1 and RASSF2), the negative regulators of K-ras, are often inactivated by methylation of the promoter region
in those tumours. However, reports showing differences in the occurrence of these alterations on the basis of tumour characteristics
have been scarce. We analysed K-ras/BRAF mutations and the methylation status of RASSF1 and RASSF2 promoter regions in 120
colorectal adenomas with respect to their clinicopathological features. K-ras/BRAF mutations and RASSF2 methylation were observed
in 49 (41%) and 30 (25%) of the samples, respectively, while RASSF1 methylation was observed in only 3 (2.5%). Adenomas with
RASSF2 methylation often carried K-ras/BRAF mutations simultaneously (22 out of 30, Po0.01). Multivariate analysis revealed that the
concomitance of these alterations was frequently observed in serrated adenomas (odds ratio (OR) 11.11; 95% confidence interval
(CI) 1.96–63.00), but rarely in adenomas located in the sigmoid or descending colon (OR 0.13; 95% CI 0.03–0.58). A comparison
between adenomas and cancers showed a significantly higher prevalence of these alterations in cancers than in adenomas in the
proximal colon (58 vs 27%, P¼0.02). Frequency and the time point of the occurrence of Ras signalling disorders differ according to
colorectal neoplasia’s characteristics, particularly the location.
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The Ras family of small guanosine triphosphatases plays essential
roles in controlling the activity of several crucial signalling
pathways (Malumbres and Barbacid, 2003). In normal cells,
Ras proteins, including H-, K-, and N-ras, are transiently activated
in response to extracellular signals and function as molecular
switches in cell proliferation. Human tumours frequently express
Ras proteins that have been activated by point mutation, although
the spectrum of Ras gene mutation varies in different cancer types
(Hidaka et al, 2000; Toyooka et al, 2006). K-ras mutation is
frequently (B45%) detected in colorectal tumours and has been
thought to be an early event in colorectal tumorigenesis, mainly
occurring during the transformation of small adenomas to
intermediate-size ones (Fearon and Vogelstein, 1990; Kinzler and
Vogelstein, 1996; Rajagopalan et al, 2002; Yuen et al, 2002). The
activated guanosine triphosphate-bound Ras then interacts with
several effector proteins, of which the Raf kinases are among
the most well characterised (O’Neill et al, 2004). Raf is a major
proliferative and antiapoptotic effector, and it was recently shown
that BRAF, one of the Raf kinases, is frequently activated by
mutation in human tumours, particularly melanomas (B70%) and
colorectal tumours (B15%) (Davies et al, 2002; Rajagopalan et al,
2002; Yuen et al, 2002).
The recent discovery of the Ras association domain family
(RASSF) protein of Ras effectors allows an explanation of at least
some of the growth-inhibitory actions of Ras. To date, RASSF1–8
have been identified (Falvella et al, 2006), and RASSF1,2,4,5 have
been shown to mediate Ras-dependent cell cycle arrest and
apoptotic death (Vos et al, 2003). Moreover, these proteins are all
frequently downregulated during tumour development by promo-
ter CpG island methylation (Dammann et al, 2003; Vos et al, 2003;
Aoyama et al, 2004; Eckfeld et al, 2004). Of these Ras effectors,
RASSF1 and RASSF2 have been shown to be involved in colorectal
tumorigenesis (van Engeland et al, 2002; Akino et al, 2005).
Previous studies have found RASSF1 methylation in 20–45%
of colorectal cancers (CRCs) (Wagner et al, 2002; van Engeland
et al, 2002; Oliveira et al, 2005; Miranda et al, 2006). Meanwhile,
Sakamoto et al (2004) have shown that the early flat-type colorectal
tumours exhibited a much higher frequency of RASSF1 methyla-
tion (81.3%). The frequency of RASSF2 methylation in CRC was
reported to be 42–73% (Akino et al, 2005; Hesson et al, 2005; Park
et al, 2006).
It is generally accepted that a large proportion of CRCs develop
from colorectal adenomas. The frequency of K-ras mutation in
adenomas was found to be lower (3–17%) than that of CRCs, and
the mutation had a strong association with larger adenoma size,
villous histology, and high-grade dysplasia (Maltzman et al, 2001;
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sBarry et al, 2006; Einspahr et al, 2006). In addition, our previous
report indicated that the laterally spreading type of adenomas,
particularly in the proximal colon, frequently carried the K-ras
mutation (Hiraoka et al, 2006). The BRAF mutation was frequently
observed in serrated adenomas and has been shown to be
significantly correlated with the recently proposed serrated
polyp-microsatellite instability pathway (Kambara et al, 2004). It
has also been shown that the K-ras and BRAF mutations are
mutually exclusive (Domingo et al, 2004; Li et al, 2006). On the
other hand, reports regarding the frequency of RASSF1 and
RASSF2 methylation in adenomas have been scarce. In addition,
clinicopathological features of colorectal tumours that carry the
methylation of either RASSF1 or RASSF2 are still largely unknown
in adenomas as well as in cancers. Moreover, the association
between K-ras/BRAF mutations and RASSF methylation, particu-
larly whether or not they work synergistically or are mutually
exclusive, is controversial in CRCs (Akino et al, 2005; Hesson et al,
2005; Park et al, 2006), and has not been sufficiently investigated in
adenomas.
In this study, therefore, we investigated K-ras and BRAF
mutations and the methylation status of RASSF1 and RASSF2 in
colorectal adenoma samples. We then examined the correlation
between these mutations and methylation based on the clinico-
pathological features of the adenomas. In particular, we focused
on locational differences in combinations of these genetic and
epigenetic alterations because a locational imbalance in each of
these alterations has been indicated (Samowitz et al, 2000;
Luchtenborg et al, 2005; Park et al, 2006). Moreover, we compared
these alterations in adenomas with those in CRCs, and examined
when these alterations are likely to occur during colorectal
carcinogenesis.
MATERIALS AND METHODS
Patients and tissue samples
Tissues of adenomas larger than 10mm were consecutively
collected from patients who underwent endoscopic polypectomy
or surgical resection of colorectal polyps at Okayama University
Hospital between June 2003 and August 2005. Tissues from
patients who had concurrent advanced CRC or a history of CRC
were excluded from analysis. Also excluded were tissues from
patients with inflammatory bowel disease or who had a known
history of familial adenomatous polyposis or hereditary non-
polyposis CRC. A total of 97 patients met the criteria and provided
written informed consent, and 120 adenomas from these patients
were analysed. At the time of resection, patient’s age and
gender, and the location, size, and macroscopic appearance of
each adenoma were determined. The anatomical distribution of
adenoma locations divided among the caecum, ascending colon,
transverse colon, descending colon, sigmoid colon, and rectum. In
this study, locational grouping was divided into three categories:
the proximal colon, including the caecum, ascending colon, and
transverse colon; the distal colon, including the descending colon
and sigmoid colon; and the rectum. Adenoma size was recorded as
the maximum diameter of the extirpated specimen. The macro-
scopic appearance of the adenomas was classified as either the
protruded type or the flat type. The flat type was defined as lesions
with a low vertical axis extending laterally along the interior
luminal wall, which is often called a laterally spreading tumour in
Japan (Kudo et al, 1997). Adenomas forming protruded morpho-
logies, other than the flat type, were designated as the protruded
type.
In addition to the adenoma samples, 65 sporadic CRC tissue
samples from patients who underwent surgical treatment at
Okayama University Hospital were also collected and analysed.
A small tissue fragment was excised from resected neoplasm for
DNA extraction, and the remaining portion was submitted for
histological diagnosis. Samples were stored at  801C until the
analysis began.
This study protocol was approved by the Institutional Review
Board of Okayama University Graduate School of Medicine,
Dentistry and Pharmaceutical Sciences, and informed consent
was obtained from each patient.
Histopathological analysis of colorectal adenomas
Histologic studies were performed on all removed adenomas. The
resected adenomas were fixed and embedded in paraffin. Serial
sections were obtained and stained with haematoxylin and eosin.
All cases were reviewed by two board certified pathologists,
and were classified as tubular, tubulovillous, villous, or serrated
adenomas. Hyperplastic polyps were not included in this analysis.
Analysis of K-ras and BRAF mutations
To detect genetic alterations in K-ras and BRAF, we analysed the
point mutations of codons 12 and 13 of the K-ras gene and the
mutation of the exon 15 codon 600 of the BRAF gene by direct
sequencing using a Big Dye Terminator v3.1, Cycle Sequencing kit,
and an ABI Genetic Analyzer 3100. The primers for K-ras sequen-
cing of codons 12 and 13 were similar to those described previously
(Hiraoka et al, 2006). The primers for sequencing the BRAF gene
were as follows: 50-TCATAATGCTTGCTCTGATAGGA-30 (forward)
and 50-TCCACTGATTAAATTTTTGGCC-30 (reverse).
Methylation analysis of RASSF1 and RASSF2
Tumour tissues were assayed for RASSF1 and RASSF2 promoter
CpG island methylation using combined bisulphite restriction
analysis (COBRA), following the report by Akino et al (2005).
Extraction and bisulphite modification of genomic DNA from neo-
plastic tissues were performed as described previously (Hiraoka
et al, 2006). Bisulphite-treated DNA was amplified by touchdown
polymerase chain reaction (PCR) using primers capable of
annealing both methylated and unmethylated alleles. Primer
sequences for RASSF1 and RASSF2, and restriction enzymes that
digest only methylated alleles were similar to those used in the
previous report (Akino et al, 2005). A touchdown thermal cycle
programme was modified in our analysis. In detail, that included
an initial denaturation for 5min at 951C, followed by three cycles
of 30s at 951C, 15s at 631C (RASSF1) or 671C (RASSF2), and 30s at
721C. The annealing temperature was then decreased by 21C until
it reached 571C (RASSF1) or 611C (RASSF2): 611C/651C (4 cycles),
591C/631C (5 cycles), and 571C/611C (28 cycles), respectively, for
RASSF1/RASSF2. A final extension for 4min at 721C was included
at the end of the cycles before holding at 121C. Samples digested
with enzymes were electrophoresed on 6% polyacrylamide gels and
visualised under ultraviolet light by staining with ethidium
bromide.
Statistical analysis
Differences in frequency were assessed by Fisher’s exact test.
Mann–Whitney U-test or Kruskal–Wallis rank test was used for
comparisons of patient age. P-values less than 0.05 were consi-
dered significant. Multiple testing was corrected by Bonferroni
correction, and Po0.017 is considered statistically significant in
the comparison among three locational groups. Univariate and
multivariate analyses were also performed to identify factors that
were independently associated with the concomitance of K-ras/
BRAF mutations and RASSF2 methylation, using a logistic
regression model with corresponding calculation of odds ratios
(ORs) and 95% confidence intervals (CIs). These analyses were
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sperformed using the SAS program (version 9.1, SAS Institute,
Cary, NC, USA).
RESULTS
Clinicopathological characteristics of patients and
adenomas
A total of 120 adenomas from 97 patients with a median age of 67
years (range 31–86) were analysed (Table 1). Of 97 patients, 79 had
one adenoma, 14 had two adenomas, 3 had three adenomas, and 1
had four adenomas. Out of 14 patients harbouring two adenomas,
9 patients had both adenomas in the same location (two in the
proximal colon, six in the distal colon, and one in the rectum).
Three or four adenomas in the same patients did not cluster in the
same location. Patients with more than one adenoma were
significantly younger than those with a single adenoma (60 vs 67
years, P¼0.02).
Of these 120 adenomas, 48 (40%) were located in the proximal
colon (11 (9%) in the caecum, 24 (20%) in the ascending colon,
and 13 (11%) in the transverse colon); 49 (41%) were in the distal
colon (9 (8%) in the descending colon and 40 (33%) in the sigmoid
colon); and 23 (19%) in the rectum. There were no significant
differences in patient age among these three locational groups
(P¼0.31).
Histological examinations revealed that 72 (60%) were tubular
adenomas, 40 (33%) were tubulovillous adenomas, and 8 (7%)
were serrated adenomas.
K-ras/BRAF mutations and RASSF1 and RASSF2
methylation
K-ras codons 12 and 13 and BRAF codon 600 point mutations of
adenomas were analysed by direct sequencing analysis. Of the 120
adenomas, 49 (41%) exhibited K-ras/BRAF mutations. Of these, 43
carried the K-ras mutation and 6 carried the BRAF mutation, and
there was no overlap between the two mutations. Mutations were
significantly more likely to be observed in females (59%, P¼0.01),
adenomas larger than 2cm (61%, Po0.01), and flat-type adenomas
(59%, Po0.01) than in the respective counterparts. K-ras mutation
was frequently detected in tubulovillous adenomas (24 out of 40,
60%), while BRAF mutation was mostly observed in serrated
adenomas (5 out of 8, 63%). The analysis of locational distribution
showed a higher prevalence of K-ras/BRAF mutations in the proxi-
mal colon (23 out of 48, 48%), and rectum (12 out of 23, 52%), and
a lower prevalence in the distal colon (14 out of 49, 29%).
Next, we analysed the methylation status of the promoter CpG
islands of RASSF1 and RASSF2 (Figure 1). Of the 120 adenomas
examined, RASSF2 methylation was observed in 30 (25%) cases,
while only 3 (2.5%) adenomas exhibited RASSF1 methylation. In
addition, 2 out of 3 adenomas with RASSF1 methylation also
showed methylation of RASSF2. Therefore, subsequent analysis
was performed on the basis of the results of RASSF2 methylation.
RASSF2 methylation was significantly more frequently observed in
large adenomas (X2cm) than in adenomas of 1–2cm (37 vs 19%,
P¼0.046). More strikingly, histopathological findings revealed
that a large proportion of serrated adenomas (6 out of 8, 75%)
exhibited RASSF2 methylation. The locational distribution of
RASSF2 methylation was similar to that of K-ras/BRAF mutations,
although the prevalence in each location was relatively low.
Prevalence was higher in the proximal colon (14 out of 48, 29%)
and rectum (9 out of 23, 39%), and lower in the distal colon (7 out
of 49, 14%) (Table 1).
Adenomas with RASSF2 methylation were more likely to carry
K-ras/BRAF mutations than those without RASSF2 methylation
(73 vs 30%, Po0.01), suggesting that these genetic and epigenetic
alterations are mutually correlated and may work synergistically.
Patients who had at least one adenoma carrying either K-ras/BRAF
mutations or RASSF2 methylation or both were significantly older
than those who had adenoma(s) without these alterations (70 vs
62 years, P¼0.01). In 18 patients harbouring plural adenomas,
2 patients each carried two adenomas with K-ras/BRAF mutations,
while no patients had two or more adenomas with RASSF2
methylation. In addition, in only 4 out of 18 (22%) patients, all of
adenomas that each patient carried exhibited the same K-ras/BRAF
and RASSF2 status (all exhibited neither K-ras/BRAF mutation nor
RASSF2 methylation). Thus, characteristics of adenomas in each
patient were not always the same regarding K-ras/BRAF mutations
or RASSF2 methylation.
Uneven locational distribution of adenomas carrying
K-ras/BRAF mutations and RASSF2 methylation
As described above, there was a locational imbalance among
K-ras/BRAF mutations or RASSF2 methylation in adenomas. To
elucidate the differences in the contribution of the Ras signalling
pathway to neoplastic development according to colonic sites, we
next investigated locational distribution of adenomas with either
K-ras/BRAF mutations or RASSF2 methylation, or both (Table 1).
Adenomas with either K-ras/BRAF mutations, RASSF2 methyla-
tion, or both were more frequently observed in the rectum than in
the distal colon (65 vs 37%, P¼0.04; and 26 vs 6%, P¼0.03,
respectively). Table 1 also shows that the prevalence of K-ras/BRAF
mutations and/or RASSF2 methylation in the proximal colon was
similar to that in the rectum (K-ras/BRAF mutations and RASSF2
methylation; 27% in the proximal colon vs 26% in the rectum,
P40.99), and thus the prevalence in the distal colon was
significantly lower than that in the proximal colon (K-ras/BRAF
mutations and RASSF2 methylation; 6 vs 27%, Po0.01). In
other words, only the adenomas in the distal colon exhibited a
distinctively lower prevalence of alterations of the Ras signalling
pathway.
Univariate and multivariate analyses of factors influencing
concomitance of K-ras/BRAF mutations and RASSF2
methylation
Our results suggested that K-ras/BRAF mutations and RASSF2
methylation can cooperate and work synergistically in adenomas.
In addition, there should be an imbalance in location or in other
characteristics of adenomas that carry these alterations. Then, to
identify factors for the concomitance of K-ras/BRAF mutations and
RASSF2 methylation in adenomas, univariate and multivariate
logistic regression analyses were performed with parameters
including gender, age, location, morphology, size, and histological
diagnosis (Table 2). In multivariate analysis, serrated adenoma
was identified as a highly significant factor for the coexistence
of K-ras/BRAF mutations and RASSF2 methylation (OR 11.11; 95%
CI 1.96–63.00). In addition, location at the distal colon (the
descending colon and sigmoid colon) was a significant factor for
the absence of alterations in the Ras signalling pathway (OR 0.13;
95% CI 0.03–0.58). No other factors were proven to be associated
with the coexistence of K-ras/BRAF mutations and RASSF2
methylation in the multivariate analysis.
K-ras/BRAF mutations and RASSF2 methylation in CRC
Lastly, we analysed K-ras/BRAF mutations and RASSF2 methyla-
tion in CRC according to colonic site. Figure 2 compares the status
of K-ras/BRAF mutations and RASSF2 methylation between
adenomas and CRCs. Among 65 CRCs, the coexistence of K-ras/
BRAF mutations and RASSF2 methylation was observed in 11 out
of 19 (58%) lesions in the proximal colon, 1 out of 19 (5%) of those
in the distal colon, and 6 out of 27 (22%) of those in the rectum. In
the distal colon, adenomas and CRCs exhibited a similarly lower
Ras signalling pathway in colorectal neoplasia
K Harada et al
1427
British Journal of Cancer (2007) 97(10), 1425–1431 & 2007 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sprevalence of disorders in the Ras signalling pathway. In addition,
in the rectum, the proportions of tumours with both K-ras/BRAF
mutations and RASSF2 methylation, with either of them, and with
neither of them, were quite similar between adenomas and CRCs.
In contrast, in the proximal colon, the proportion of tumours with
both K-ras/BRAF mutations and RASSF2 methylation was
significantly higher in CRCs (58%) than in adenomas (27%)
(P¼0.02). These results suggest that in the proximal colon,
disorders of the Ras signalling pathway are almost requisite for
development into carcinoma, while in the rectum two types of
cancer development may exist: pathways associated with disorders
of Ras signalling and those that are not. In the distal colon, the
major route of CRC development does not seem to require
disorders of the Ras signalling pathway.
DISCUSSION
In the current study, we examined K-ras/BRAF mutations and
methylation status of RASSF1 and RASSF2 in colorectal adenomas
in relation to clinicopathological features. We also compared these
genetic and epigenetic alterations in adenomas with those in
cancers. Our results revealed that these genetic and epigenetic
alterations were likely to occur concomitantly in each colorectal
tumour. Furthermore, tumours with these alterations showed
uneven locational distribution in the colorectum, and the
distributions were a little different between adenomas and cancers.
Previous reports have shown differences between the right-side
colon (including the caecum, ascending colon, and transverse
colon) and the left-side colon (including the descending colon,
sigmoid colon, and rectum) in epidemiologic incidence (Gonzalez
et al, 2001), morphology (Okamoto et al, 2005), and molecular
alterations (Iacopetta, 2002; Azzoni et al, 2007). Meanwhile, other
reports revealed these differences between the colon and rectum
(Frattini et al, 2004; Kim et al, 2006). Also regarding K-ras/BRAF
mutations, several reports have shown a higher prevalence of K-ras
mutation in the rectum than in the colon (Luchtenborg et al, 2005;
Barry et al, 2006; Einspahr et al, 2006), while other reports
compared K-ras mutation between the proximal colon and the
distal colon, and found dominance in the former (Samowitz et al,
2000; Miranda et al, 2006). BRAF mutation is also known to be
associated with the proximal localisation (Li et al, 2006). Our
results seem consistent with these previous reports. Moreover, our
results indicated that K-ras/BRAF mutations in adenomas were
Table 1 Clinicopathological features of adenomas with K-ras/BRAF mutations and/or RASSF2 methylation
K-ras/BRAF
mutations
RASSF2
methylation
K-ras/BRAF mutations or
RASSF2 methylation
K-ras/BRAF mutations and
RASSF2 methylation
All adenomas n (%) P value n (%) P value n (%) P value n (%) P value
Total 120 49 (41) 30 (25) 57 (48) 22 (18)
Gender
Female 34 20 (59) 0.01 11 (32) 0.25 23 (68) o0.01 8 (24) 0.43
Male 86 29 (34) 19 (22) 34 (40) 14 (16)
Age
Median (range)
a 66 (31–86) 70 (31–86) 70 (31–86) 70 (31–86) 71 (31–86)
o65 59 20 (34) 0.14 11 (19) 0.14 23 (39) 0.07 8 (14) 0.24
X65 61 29 (48) 19 (31) 34 (56) 14 (23)
Location
Proximal colon
b 48 23 (48) 0.06
d
0.80f14 (29) 0.09
d
0.43f 24 (50) 0.22
d
0.31f 13 (27) o0.01
d
40.99f
Distal colon
c 49 14 (29) 0.07
e 7 (14) 0.03
e 18 (37) 0.04
e 3 (6) 0.03
e
Rectum 23 12 (52) 9 (39) 15 (65) 6 (26)
Macroscopic appearance
Protruded 79 25 (32) o0.01 17 (22) 0.27 29 (37) o0.01 13 (16) 0.47
Flat type 41 24 (59) 13 (32) 28 (68) 9 (22)
Size
o2cm 79 24 (30) o0.01 15 (19) 0.046 27 (34) o0.01 12 (15) 0.22
X2cm 41 25 (61) 15 (37) 30 (73) 10 (24)
Histopathology
Tubular 72 18 (25) o0.01 12 (17) o0.01 23 (32) o0.01 7 (10) o0.01
Tubulovillous 40 24 (60) 12 (30) 26 (65) 10 (25)
Serrated 8 7 (88) 6 (75) 8 (100) 5 (63)
aMedian age is calculated based on the number of patients.
bProximal colon, including the cecum, the ascending colon, and the transverse colon.
cDistal colon, including the
descending colon and the sigmoid colon.
dProximal colon vs distal colon.
eDistal colon vs rectum.
fProximal colon vs rectum.
] ] ] ]
A1
RASSF1
RASSF2
A2 C1 C2 HCT116 RKO H2O
M
M
Figure 1 Analysis of methylation status of RASSF1 and RASSF2
promoter CpG island. COBRA was carried out using bisulphite-treated
DNA from colorectal adenomas and cancers. A representative result for
tumour tissue samples with/without RASSF1 or RASSF2 promoter
methylation is shown. A1 is a sample without RASSF1 and RASSF2
methylation. A2 and C2 are samples with RASSF2 methylation, and without
RASSF1 methylation. C1 is a sample with RASSF1 methylation, and without
RASSF2 methylation. A, adenoma samples; C, cancer samples; M,
methylated alleles; HCT116, colon cancer cell line used as a negative
control for RASSF1 and RASSF2 methylation; RKO, colon cancer cell line
used as a positive control for RASSF1 and RASSF2 methylation; H2O,
sample without DNA.
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ssignificantly less frequent in the distal colon than in either the
proximal colon or the rectum. This suggests that K-ras/BRAF
mutations are less important to neoplasia in the distal colon,
although neoplasm occurs in greater numbers in the distal colon
than in the other locations.
Meanwhile, only a few reports have referred to the correlation
between clinicopathological features of colorectal neoplasia and
methylation status of RASSF genes. Particularly scarce are reports
regarding this issue in adenomas. We found that RASSF2
methylation was, like K-ras/BRAF mutations, frequently observed
in large adenomas and in serrated adenomas. Moreover, the
locational distribution of adenomas with this epigenetic alteration
was also similar to that of adenomas with K-ras/BRAF mutations,
although the frequency of the epigenetic change as a whole was
lower than that of the genetic changes. As a result, genetic and
epigenetic alterations in the Ras signalling pathway are likely to
coexist and may work synergistically even in adenomas. These
cooperative alterations were frequently observed in adenomas in
the proximal colon and the rectum, while, as the multivariate
analysis showed, those alterations were relatively rare in adenomas
in the distal colon. These findings suggest that an alternative
carcinogenic pathway other than the Ras signalling pathway may
function in the distal colon.
In this study, we examined the methylation status of RASSF1
and RASSF2, because the methylation of these two genes among
the RASSF series was reported to be specifically correlated with
CRC development (van Engeland et al, 2002; Hesson et al, 2005).
However, methylation of RASSF1 in colorectal neoplasm was
relatively infrequent in our study (3% in adenomas and 12% (data
not shown) in CRCs). Previous reports showed a higher prevalence
of RASSF1 methylation in CRC (20–45%) (van Engeland et al,
2002; Wagner et al, 2002; Oliveira et al, 2005; Miranda et al, 2006).
Furthermore, Sakamoto et al (2004) reported that 81.3% of flat-
type tumours exhibited RASSF1 methylation. However, all of these
previous reports used methylation-specific PCR (MSP) or its
modified version as the methodology for detecting methylation.
Since MSP has been shown to be too sensitive, resulting in
overestimation of methylation status, the positive results of MSP
are not always consistent with the loss of function of the gene. In
contrast, we used COBRA, a stricter methodology than MSP,
following the method of Akino et al (2005) (Hiraoka et al, 2006).
COBRA for RASSF1 has been proven to be correlated with its gene
function (Akino et al, 2005), and our results were close to theirs
(13% in CRCs and 6% in adenomas). In this regard, RASSF1
methylation would be less important than has been considered
thus far.
In the case of RASSF2, there is a problem similar to that with
RASSF1 regarding the interpretation of experimental results. The
majority of reports adopted MSP as the experimental procedure,
and reported a higher prevalence of methylation (70–73% in CRCs
and 88–100% in adenomas) (Hesson et al, 2005; Park et al, 2006)
than in our study (46% in CRCs and 25% in adenomas) or Akino
et al.’s study (42% in CRCs and 43% in adenomas). However, the
methylation frequency of RASSF2 in colorectal neoplasia was
much higher than that of RASSF1 even in our results. Thus, the
methylation of RASSF2, but not that of RASSF1, should have a
distinct function during CRC development.
There were differences between adenomas and cancers in the
locational distribution of neoplasm with genetic and/or epigenetic
alterations of the Ras signalling pathway, although similar trends
were observed (Figure 2). The most striking difference was seen in
the proximal colon. Some adenomas in the proximal colon carried
neither K-ras/BRAF mutations nor RASSF2 methylation, while
there were few cancers without these alterations. This suggested
that disorders in the Ras signalling pathway can occur in the
proximal colon neoplasia not only during the early period but also
during the late period of cancer progression. Then we can propose
three types of cancer development with respect to the Ras
signalling pathway. The first type is, as frequently seen in the
distal colon neoplasms and in some rectal neoplasms, a tumour
with no Ras signalling pathway alterations. The next type is, as has
been widely believed thus far, a tumour in which disorder of the
Ras signalling pathway occurs during the early period of cancer
development. This type was seen in a large proportion of rectal
tumours as well as in some tumours in the proximal colon. The
third type, observed mainly in the proximal colon as shown above,
is a tumour in which disorder of the Ras signalling pathway occurs
during the late period of cancer development. Thus, our results
suggest that both the likelihood of involvement of Ras signalling
Table 2 Univariate and multivariate analyses of factors for adenomas carrying both K-ras/BRAF mutations and RASSF2 methylation
Both K-ras/BRAF mutation and RASSF2 methylation
All adenomas n (%) Univariate analysis OR (95% CI) Multivariate analysis OR (95% CI)
Total 120 21 (18)
Female 34 8 (24) 1.73 (0.64–4.64) 1.51 (0.50–4.53)
Age (X65) 61 14 (23) 2.21 (0.82–5.95) 1.56 (0.54–4.53)
Distal colon 49 3 (6) 0.19 (0.05–0.69)
w 0.13 (0.03–0.58)
z
Flat type 41 9 (22) 1.43 (0.55–3.69) 0.54 (0.16–1.84)
Size (X2cm) 41 10 (24) 1.99 (0.77–5.19) 1.86 (0.59–5.94)
Serrated adenoma 8 5 (63) 10.00 (2.17–46.00)* 11.11 (1.96–63.00)**
Abbreviations: OR, odds ratio; CI, confidence interval.
wP¼0.01,
zP¼0.007, *P¼0.003, **P¼0.007.
Having neither K-ras/BRAF mutations nor RASSF2 methylation 
Having either K-ras/BRAF mutations or  RASSF2 methylation
Having both K-ras/BRAF mutations and RASSF2 methylation
Adenoma Cancer
Figure 2 Locational distributions of adenomas and cancers with K-ras/
BRAF mutation and/or RASSF2 methylation. Cancers with K-ras/BRAF
mutation and/or RASSF2 methylation exhibit locational distribution similar
to that of adenomas. However, the proportion of tumours in the proximal
colon with both K-ras/BRAF mutation and RASSF2 methylation was
significantly higher in cancers (58%) than in adenomas (27%) (P¼0.02).
Arrowheads indicate serrated adenomas.
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disorder is likely to occur differ according to tumour location.
We found that RASSF2 was frequently methylated in serrated
adenomas. Recent reports have shown that serrated adenomas
have biological features distinct from other conventional adeno-
mas or hyperplastic polyps. In particular, these tumours are
characterised by a high frequency of carrying BRAF mutation and
a high frequency of CpG island methylation (CpG island
methylator phenotype-high) (Park et al, 2003; Kambara et al,
2004; O’Brien et al, 2004), and are considered precursor lesions of
CRC with microsatellite instability. Consistent with previous
reports, in our study, BRAF mutation was frequently observed in
serrated adenomas (5 out of 8, 63%). In addition, most of serrated
adenomas carried RASSF2 methylation (6 out of 8, 75%).
Consequently, serrated adenomas were likely to have both K-ras/
BRAF mutations and RASSF2 methylation (5 out of 8, 63%),
despite relatively dispersed locational distribution (Figure 2). As
previously reported, methylation of RASSF2 in those tumours may
be affected by CpG island methylator phenotype status (Minoo
et al, 2006). Alternatively, however, a specific synergistic correla-
tion between BRAF mutation and RASSF2 methylation may
function in Ras signalling disorders during the progression of
serrated adenomas.
There are limitations to our study. In particular, selection bias of
collected tumours may inevitably exist even though tumours were
collected consecutively. Because our institute is a tertiary care
gastroenterology facility, patients with tumours that could not be
easily treated in other hospitals were likely to be referred to our
hospital. As a result, our collected series may be composed of
uncommon fractions of colorectal neoplasm. In fact, the propor-
tions of flat-type adenomas and rectal carcinomas were relatively
high in our study. The relatively small number of adenoma
samples as well as that of cancer samples would also be a
limitation.
In conclusion, we demonstrated that RASSF2 methylation is
of importance as well as K-ras/BRAF mutations during the
progression of colorectal tumours. In addition, these genetic
and epigenetic alterations in the Ras signalling pathway are
likely to function synergistically. More importantly, however,
both the likelihood and time point of the occurrence of these
alteration differ according to tumour location. These results
suggest that disorders in the Ras signalling pathway are not
uniformly involved in the development of CRC. Frequency and the
time point of the occurrence of Ras signalling disorders differ
according to colorectal neoplasia’s characteristics, particularly the
location.
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